NCT06974734 - A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies | Biotech Hunter

Enrollment

399

Participants

Timeline

Start Date

May 6, 2025

Primary Completion Date

September 30, 2028

Study Completion Date

September 30, 2029

Conditions

Carcinoma, Non Small Cell LungCarcinoma, Pancreatic DuctalMalignant MelanomaSquamous Cell Carcinoma of the Head and Neck (SCCHN)

Interventions

DRUG

PF-08046037

Given into the vein (IV; intravenous)

DRUG

sasanlimab

Given under the skin (SQ; subcutaneous)

Trial Locations (17)

37203

RECRUITING

Sarah Cannon Research Institute - Pharmacy, Nashville

RECRUITING

SCRI Oncology Partners, Nashville

RECRUITING

Tristar Centennial Medical Center, Nashville

46219

RECRUITING

Community Health Network, Inc, Indianapolis

46227

RECRUITING

Community Health Network, Inc., Indianapolis

46250

RECRUITING

Community Health Network, Inc., Indianapolis

46256

RECRUITING

Community Health Network, Inc., Indianapolis

49546

RECRUITING

START Midwest, Grand Rapids

78229

NOT_YET_RECRUITING

Methodist Hospital, San Antonio

NOT_YET_RECRUITING

START San Antonio, San Antonio

80218

RECRUITING

Presbyterian/ St. Lukes Medical Center, Denver

RECRUITING

Sarah Cannon Research Institute at HealthONE, Denver

06510

NOT_YET_RECRUITING

Smilow Cancer Hospital - Yale New Haven Health, New Haven

NOT_YET_RECRUITING

Yale - New Haven Hospital - Yale Cancer Center, New Haven

06511

NOT_YET_RECRUITING

Smilow Cancer Hospital Phase 1 Unit, New Haven

06611

NOT_YET_RECRUITING

Smilow Cancer Hospital - Trumbull, Trumbull

00935

RECRUITING

Pan American Center for Oncology Trials, LLC, Rio Piedras